Moderna

Rothschild Redburn downgraded Moderna (MRNA) to Sell with an $81 price target. The analyst called the Phase 3 melanoma vaccine result 'a great result' but said the stock now appears to price in broad use across multiple tumor types where there is little or no supporting data.

Moderna is raising $2B via convertible senior notes due 2032, with an option for an extra $300M. The FDA also approved its updated 2026-2027 COVID-19 vaccines, including the new MnExSpike formula.

An 87-year-old melanoma trial participant bought Moderna (MRNA) stock when he enrolled in an experimental mRNA cancer vaccine study two years ago, per WSJ. The stock rose more than 150% last week on successful trial results.

Moderna and Merck reported their personalized mRNA cancer vaccine succeeded in a Phase 3 trial for melanoma. AI reportedly helped design the vaccine.

Merck and Moderna announced positive Phase 3 results for intismeran autogene, an mRNA personalized cancer vaccine, combined with Keytruda in melanoma. The trial met recurrence-free and distant metastasis-free survival endpoints. Full data to be presented at a medical meeting; regulatory submissions to begin.

An unverified report claims Moderna shares dropped 18%. No further details are available. The source is unconfirmed.

Trump bought Moderna, $MRNA. He bought up to $50,000 of $MRNA on March 2, bought again on March 17, and only partially sold in May. It was up more than 150% yesterday.

Ro Khanna bought Moderna stock in June; shares surged in August on trial results.

FDA approves Moderna's first mRNA flu vaccine.